Autumn Roque, DNP, APRN, PMHNP-BC

An FDA committee recently decided the clozapine REMS protocol was no longer necessary. How will this impact clinicians?

The authors of the Clinician's Corner column discuss the latest FDA-approved treatment for schizophrenia.

The context and timing of symptoms is critical for a timely and accurate bipolar diagnosis.

Diagnostic clarity between anhedonia and persistent depressive disorder is paramount in clinical practice to ensure effective and safe treatment for patients.